TY - JOUR ID - 87381 TI - Does Salvage Chemotherapy Regimen Intensity Embark on Clearance of Bone Marrow Neuroblastoma? JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Fawzy, Mohamed AU - Hamoda, Asmaa AU - Elhemaly, Ahmed AU - Elkinaai, Naglaa AU - Soliman, Sonya AU - Reda, Hala AU - Elmenawi, Salma AU - Moussa, Emad AD - Department of Pediatric Oncology, Children Cancer Hospital Egypt-57357 and National Cancer Institute (NCI), Cairo University, Cairo, Egypt. AD - Department of Pathology, Children Cancer Hospital Egypt-57357 and National Cancer Institute (NCI), Cairo University, Cairo, Egypt. AD - Department of Clinical Pathology, Children Cancer Hospital Egypt-57357 and National Cancer Institute (NCI), Cairo University, Cairo, Egypt. AD - Clinical Research Unit, Research Department, Children Cancer Hospital Egypt-57357 and National Cancer Institute (NCI), Cairo University, Cairo, Egypt. Y1 - 2019 PY - 2019 VL - 20 IS - 5 SP - 1519 EP - 1524 KW - neuroblastoma KW - refractory bone marrow KW - ICE KW - Topotecan/Cyclophosphamide DO - 10.31557/APJCP.2019.20.5.1519 N2 - Introduction: Neuroblastoma (NBL) is the most common extracranial solid tumor in children. It accounts for 15%of the deaths from cancer in the pediatric age group. Approximately half of the newly diagnosed children are at “highrisk” (HR) of treatment failure. This study aim was to evaluate the impact of salvage chemotherapy ICE (ifosfamide,carboplatin, and etoposide) versus TC (topotecan/cyclophosphamide) when administered to NBL HR patients havingresidual bone marrow disease after primary tumor control on the first line treatment regimen. Materials and Methods:The present retrospective study included two groups of eligible stage 4 NBL patients with persistent bone marrowdisease. Group (1), 29 patients, received ICE whereas less intensive TC was administered to Group (2), 32 patients.Data analysis included epidemiological variables, pathology subtype, MYCN gene status, primary tumor responseand their correlation with bone marrow disease clearance on each regimen. Results: A higher tendency of completebone marrow clearance was reported in patients who received ICE compared to TC; 41.4% versus 25.0%, respectively.However, the difference was not statistically significant (p= 0.174). Conclusion: TC regimen appears to be a goodalternative to ICE as salvage treatment in an attempt to clear NBL bone marrow residual, with the privilege of beingless toxic and can be given on outpatient basis. Further randomized trials of larger study sample size with survivalimpact analysis are warranted. UR - https://journal.waocp.org/article_87381.html L1 - https://journal.waocp.org/article_87381_8a2aa85cb3397932b7695238331a4cf3.pdf ER -